Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The SEEK spin-out ConserV Bioscience is developing a broad-spectrum coronavirus vaccine, aiming to get ahead of the arrival of new strains of the virus.
Set to provide a COVID-19 vaccine partnered with AstraZeneca/Oxford to COVAX and various governments from Brazil to South Africa, India's Serum Institute assures that a fire at one of its units under construction will not impact supplies.
The company will seek emergency use authorization to prevent outbreaks in nursing homes. Regeneron is also positioning its antibody cocktail to prevent infections.
Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.
The Israel-based, NASDAQ-listed biotech tells Scrip that if the oral SK2 selective inhibitor succeeds in a Phase II/III study, it would be "very comfortable" taking opaganib all the way to market on its own.
Roche's Actemra is a major player in this space, but Humanigen is looking to take it on directly.
Our graphic tracker of key developments from emergency authorized vaccines, the global roll-out, and late-stage vaccine candidates.
The company is developing a vaccine with both adenoviral and mRNA technology that could potentially overcome resistance mutations on the SARS-CoV-2 spike protein.
The Israeli biotech which is listed on the NASDAQ is in for a busy 2021 with strong marketing pushes for Movantik, Aemcolo and Talicia and completing a pivotal trial for COVID-19 hopeful opaganib.
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
Additional views from the virtual J.P. Morgan Healthcare Conference on ways the COVID-19 pandemic has affected business practices and lessons learned for the future.
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.
One year after the first cases of a novel coronavirus emerged in Wuhan, a team from the World Health Organization has arrived in the city to investigate its origin. Meanwhile, mixed results are reported for some of the leading Chinese vaccines being developed to fight the pandemic still wreaking global havoc.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.